Gene · 1870
Papers2,847
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,847
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Lactate-lactylation in tumor angiogenesis and progression: mechanisms, biomarker potential, and therapeutic implications. | Biomark Res | 2026 | 41593811 | PubTator, text mining | PubMed |
| Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. | Nat Commun | 2026 | 41593097 | PubTator, text mining | PubMed |
| HMGB1 affects the progression of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors through E2F2. | Cancer Cell Int | 2026 | 41580779 | PubTator, text mining | PubMed |
| Epigenetic dysregulation of B‑cells in autoimmune diseases and lymphomas (Review). | Int J Mol Med | 2026 | 41574706 | PubTator, text mining | PubMed |
| MiR-31 suppresses lung adenocarcinoma cell proliferation through CDK1 and E2F2-mediated cell cycle arrest. | Discov Oncol | 2026 | 41511728 | PubTator, text mining | PubMed |
| The interplay between the extracellular matrix and extracellular vesicle-associated microRNAs. | Cell Commun Signal | 2026 | 41495757 | PubTator, text mining | PubMed |
| E2F2 promotes asthmatic lung injury and airway remodeling by regulating NBR1-mediated epithelial-mesenchymal transition. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 41420736 | PubTator, text mining | PubMed |
| ACSL4 coordinates metabolic and cell cycle reprogramming to promote endometrial cancer progression. | Cell Signal | 2026 | 41260237 | PubTator, text mining | PubMed |
| Inhibition of the YAP-E2F2-FGF2 axis in renal tubular cells ameliorates renal fibrosis in chronic kidney disease. | Sci China Life Sci | 2026 | 40947460 | PubTator, text mining | PubMed |
| E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p. | Hepatology | 2026 | 40720724 | PubTator, text mining | PubMed |
| Prognostic Significance of HMGA1 in Hepatocellular Carcinoma: Implications for Tumor Progression and Targeted Therapy. | Arch Iran Med | 2025 | 41778427 | PubTator, text mining | PubMed |
| Novel Therapeutic Strategy for Renal Cell Carcinoma: Niclosamide Enhances Sunitinib Efficacy via DNA Repair and Cell Cycle Pathways. | Int J Mol Sci | 2025 | 41303409 | PubTator, text mining | PubMed |
| Cell-type-agnostic differential gene expression uncovers conserved principles of cellular regulation. | bioRxiv | 2025 | 41256422 | PubTator, text mining | PubMed |
| C1orf50 Accelerates Epithelial-Mesenchymal Transition and the Cell Cycle of Hepatocellular Carcinoma. | Cancer Genomics Proteomics | 2025 | 41151851 | PubTator, text mining | PubMed |
| Integrated bioinformatics and molecular docking analysis reveal potential hub genes and targeted therapeutics in sepsis-associated acute lung injury. | Front Immunol | 2025 | 41142807 | PubTator, text mining | PubMed |
| NR2F6 regulates Temozolomide resistance in glioma via the E2F2-PARP1 pathway. | Cancer Cell Int | 2025 | 41121148 | PubTator, text mining | PubMed |
| NPR1 modulates DNA replication in vascular endothelial cells via the transcription factor E2F2. | Genes Genomics | 2025 | 41071534 | PubTator, text mining | PubMed |
| Integrated analysis and experimental validation of E2F2 as a potential prognostic biomarker and its oncogenic roles in serous ovarian cancer. | Front Mol Biosci | 2025 | 41064634 | PubTator, text mining | PubMed |
Correction: Upregulation of miR-155-5p impaired ginsenoside Rg1-mediated wound healing in diabetic foot ulcers by targeting E2F2/CDCA7L signaling : Rg1 improves DFU wound healing via inhibiting miR-155-5p. | Mol Biol Rep | 2025 | 40956456 | PubTator, text mining | PubMed |
| Identification of sepsis biomarkers through glutamine metabolism-mediated immune regulation: a comprehensive analysis employing mendelian randomization, multi-omics integration, and machine learning. | Front Immunol | 2025 | 40909263 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1870/papers?page=3